Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00040014
Status:
TERMINATED
Last Update Posted:
2012-02-16
First Post:
2002-06-18
Brief Title:
Open Label Multicenter Randomized Controlled Study of IM or Oral Exemestane Aromasin in Postmenopausal Women
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Open Label Multicenter Randomized Controlled Study of IM or Oral Exemestane Aromasin in Postmenopausal Women With Advanced Breast Cancer Having Progressed on Tamoxifen
Status:
TERMINATED
Status Verified Date:
2012-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to find out if the two different formulations of exemestane Aromasin oral and injectable are equivalent in terms of pharmacodynamics and pharmacokinetics ie if ultimately both formulations have the same efficacy in postmenopausal women with metastatic breast cancer who have failed previous antiestrogens therapy and are equally safe
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None